| APLS Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the APLS shares outstanding history going back to 11/9/2017:
Also see: APLS Market Cap History APLS YTD Return |
APLS Shares Outstanding History — Apellis Pharmaceuticals Share Count Over Time
As of 4/30/2026 Apellis Pharmaceuticals has 128.02 million APLS shares outstanding. Investors often track the APLS shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows APLS share count trends over time, with 39 historical shares outstanding datapoints presented, dating back to 11/9/2017.
| APLS Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
APLS Historical Shares Outstanding: +11.93% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| APLS Stock Price Chart |
| About Apellis Pharmaceuticals Inc |
| Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. Co. is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Co.'s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. We show 39 historical shares outstanding datapoints in our coverage of APLS's shares outstanding history. Understanding the changing numbers of APLS shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like APLS versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching APLS by allowing them to research APLS shares outstanding history as well as any other stock in our coverage universe. |
| APLS Current Stock Quote |
Quotes delayed 20 minutes  Free APLS Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| APLS Share Performance |
| Shares Outstanding Peers |
| Apellis Pharmaceuticals (APLS) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
APLT Shares Outstanding History APM Shares Outstanding History APR Shares Outstanding History APRE Shares Outstanding History APRI Shares Outstanding History APTX Shares Outstanding History APVO Shares Outstanding History APYX Shares Outstanding History AQST Shares Outstanding History AQXP Shares Outstanding History More Healthcare companies » |
APLS Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
